Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. The Danish ...

Corvidia’s lead drug candidate – interleukin-6 inhibitor ziltivekimab (formerly COR-001) – is being developed as a therapy for reducing the risk of cardiovascular problems in CKD who have ...